Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Adjusted Financial Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial ratios presented demonstrate varied trends over the five-year period. Generally, adjusted ratios exhibit similar patterns to their reported counterparts, though magnitude differences exist. Asset turnover, liquidity, leverage, and profitability metrics all show distinct movements, suggesting evolving financial performance.
- Asset Turnover
- Reported total asset turnover initially increased from 0.41 to 0.46 before declining to 0.40. The adjusted ratio mirrors this trend, moving from 0.42 to 0.47 and then back to 0.41. This suggests a slight initial improvement in asset utilization followed by a return towards earlier levels. The difference between reported and adjusted values remains relatively consistent.
- Liquidity
- Both the reported and adjusted current ratios demonstrate an improving liquidity position. Starting at 1.50 and 1.51 respectively, both ratios increased consistently, reaching 1.89 and 1.91 by the end of the period. This indicates a strengthening ability to meet short-term obligations. The adjustments have a minimal impact on the observed trend.
- Leverage
- Debt to equity and debt to capital ratios both decreased from 2021 to 2024, indicating a reduction in financial leverage. The reported debt to equity ratio fell from 0.85 to 0.63, while the adjusted ratio decreased from 0.83 to 0.65. A slight increase is then observed in 2025 for both reported and adjusted values. The adjusted ratios consistently show slightly lower leverage than reported figures. Financial leverage followed a similar pattern, decreasing from 2.33 to 1.96 before increasing to 2.07.
- Profitability
- Reported net profit margin experienced a decline from 19.70% to 13.99% before recovering to 15.05%. The adjusted net profit margin shows a more pronounced decrease, falling from 19.31% to 10.59% and then rising to 14.20%. This suggests that adjustments significantly impact the reported profitability figures. Return on equity (ROE) followed a similar downward trend, with reported ROE decreasing from 18.94% to 12.55% and adjusted ROE falling from 17.22% to 11.82%. Return on assets (ROA) also decreased, from 8.12% to 6.08% reported and 8.03% to 5.82% adjusted, indicating a diminishing ability to generate profit from assets.
In summary, the company experienced a period of fluctuating asset utilization, improved liquidity, reduced leverage, and declining profitability, as reflected in these adjusted financial ratios. The adjustments applied consistently alter the magnitude of the ratios, particularly impacting profitability measures, but do not fundamentally change the observed trends.
Thermo Fisher Scientific Inc., Financial Ratios: Reported vs. Adjusted
Adjusted Total Asset Turnover
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Total asset turnover = Revenues ÷ Total assets
= ÷ =
2 Adjusted total assets. See details »
3 2025 Calculation
Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= ÷ =
The analysis reveals trends in revenue, total assets, and associated asset turnover ratios over a five-year period. Revenues exhibited an initial increase followed by a slight decline and subsequent recovery. Total assets generally increased, with a notable jump in the final year examined. Both reported and adjusted total asset turnover ratios demonstrate fluctuations throughout the period.
- Revenues
- Revenues increased from US$39,211 million in 2021 to US$44,915 million in 2022, representing a growth of approximately 14.3%. A decrease was then observed in 2023, with revenues falling to US$42,857 million. Revenues remained relatively stable in 2024 at US$42,879 million before increasing again to US$44,556 million in 2025.
- Total Assets
- Total assets increased steadily from US$95,123 million in 2021 to US$98,726 million in 2023. A slight decrease occurred in 2024, with total assets reported at US$97,321 million. A more substantial increase was observed in 2025, reaching US$110,343 million, indicating a significant expansion of the asset base.
- Reported Total Asset Turnover
- The reported total asset turnover ratio increased from 0.41 in 2021 to 0.46 in 2022, suggesting improved asset utilization. This was followed by a decrease to 0.43 in 2023 and a slight increase to 0.44 in 2024. The ratio decreased again in 2025 to 0.40, indicating a less efficient use of assets in generating revenue compared to the peak in 2022.
- Adjusted Total Assets & Turnover
- Adjusted total assets mirrored the trend of reported total assets, increasing from US$94,265 million in 2021 to US$108,748 million in 2025, with similar fluctuations in 2023 and 2024. The adjusted total asset turnover ratio followed a similar pattern to the reported ratio, rising from 0.42 in 2021 to 0.47 in 2022, then decreasing to 0.44 in 2023 and remaining at 0.44 in 2024, before falling to 0.41 in 2025. The consistency between the reported and adjusted ratios suggests that the adjustments made to total assets do not significantly alter the overall assessment of asset utilization.
Overall, the period demonstrates a dynamic relationship between revenue generation and asset deployment. While revenue experienced growth, the asset turnover ratios suggest potential areas for improved efficiency, particularly in the most recent year examined.
Adjusted Current Ratio
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Adjusted current assets. See details »
3 Adjusted current liabilities. See details »
4 2025 Calculation
Adjusted current ratio = Adjusted current assets ÷ Adjusted current liabilities
= ÷ =
The adjusted current ratio exhibited a generally positive trend over the five-year period, demonstrating fluctuations but ultimately showing improvement. Initial values were relatively stable, followed by a strengthening position in the later years. A comparison between the reported and adjusted ratios suggests minor differences in the overall liquidity picture, with the adjustments generally leading to slightly higher ratios.
- Adjusted Current Ratio - Overall Trend
- The adjusted current ratio began at 1.51 in 2021 and experienced a slight decrease to 1.50 in 2022. A subsequent increase was observed in 2023, reaching 1.78, followed by a modest decline to 1.68 in 2024. The ratio concluded the period with a further increase to 1.91 in 2025. This indicates an overall strengthening of the company’s ability to cover short-term liabilities with short-term assets when considering the adjustments made.
- Comparison with Reported Current Ratio
- The adjusted current ratio consistently remained close to the reported current ratio throughout the period. The difference between the two ratios was minimal in each year, suggesting that the adjustments to current assets and liabilities did not substantially alter the overall assessment of short-term liquidity. The adjusted ratio was consistently slightly higher than the reported ratio.
- Year-over-Year Changes
- The largest year-over-year increase in the adjusted current ratio occurred between 2022 and 2023, rising from 1.50 to 1.78. The increase from 2024 to 2025 was also notable, moving from 1.68 to 1.91. The decrease from 2021 to 2022 was minimal, and the decrease from 2023 to 2024 was also relatively small. These changes suggest periods of more significant improvement in short-term liquidity followed by periods of stabilization or slight retraction.
- Adjusted Current Assets and Liabilities
- Adjusted current assets mirrored the trend in the adjusted current ratio, with increases observed in 2022, 2023, and 2025. Adjusted current liabilities generally decreased or remained stable, contributing to the improved ratio. The adjustments to both assets and liabilities appear to have a combined effect of enhancing the short-term liquidity position.
Adjusted Debt to Equity
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Adjusted total debt. See details »
3 Adjusted total equity. See details »
4 2025 Calculation
Adjusted debt to equity = Adjusted total debt ÷ Adjusted total equity
= ÷ =
The adjusted debt to equity ratio for the period demonstrates a generally stable, though slightly increasing, trend over the five years examined. While fluctuations occur, the ratio remains within a relatively narrow range, suggesting consistent capital structure management. Initial values indicate a ratio of 0.83 in 2021, followed by 0.78 in 2022, and 0.76 in 2023. A decrease to 0.65 is observed in 2024, before rising again to 0.76 in 2025.
- Adjusted Debt to Equity Ratio - Overall Trend
- The adjusted debt to equity ratio exhibits a modest increase from 2021 to 2025, moving from 0.83 to 0.76. This suggests a slight reliance on debt financing relative to equity over the period, although the change is not substantial. The dip in 2024 warrants further investigation to understand the contributing factors.
- Year-over-Year Changes
- From 2021 to 2022, the adjusted debt to equity ratio decreased from 0.83 to 0.78, indicating a reduction in relative debt. A further slight decrease occurred between 2022 and 2023, moving from 0.78 to 0.76. The most significant change is observed between 2023 and 2024, with a decrease of 0.11, from 0.76 to 0.65. This is followed by an increase of 0.11 between 2024 and 2025, returning the ratio to 0.76.
- Underlying Components
- Adjusted total debt increased from US$36,339 million in 2021 to US$40,855 million in 2025. Simultaneously, adjusted total equity grew from US$43,973 million to US$53,505 million over the same period. The increase in equity appears to be outpacing the increase in debt, contributing to the overall stability of the ratio, despite the fluctuations.
The observed fluctuations in the adjusted debt to equity ratio, particularly the decrease in 2024 followed by a rebound in 2025, suggest potential strategic shifts in financing or equity management. Further analysis, considering the specific events and financial decisions made during those years, would be necessary to fully understand these movements.
Adjusted Debt to Capital
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Adjusted total debt. See details »
3 Adjusted total capital. See details »
4 2025 Calculation
Adjusted debt to capital = Adjusted total debt ÷ Adjusted total capital
= ÷ =
The information presents a five-year trend of debt and capital figures, culminating in adjusted debt-to-capital ratios. Total debt exhibited a generally stable pattern between 2021 and 2023, fluctuating around the US$34-35 billion mark, before decreasing in 2024 and increasing again in 2025. Total capital consistently increased over the period, moving from US$75.7 billion in 2021 to US$92.8 billion in 2025.
- Reported Debt to Capital
- The reported debt-to-capital ratio demonstrated a slight decline from 0.46 in 2021 to 0.39 in 2024, before increasing marginally to 0.42 in 2025. This suggests a decreasing reliance on debt financing relative to capital over the majority of the period, with a slight reversal in the most recent year.
- Adjusted Total Debt
- Adjusted total debt mirrored the trend of total debt, remaining relatively consistent between 2021 and 2023, decreasing in 2024, and then increasing in 2025. The adjusted figures are consistently higher than the reported total debt, indicating the presence of adjustments that increase the reported debt value.
- Adjusted Total Capital
- Adjusted total capital also showed a consistent upward trend, increasing from US$80.3 billion in 2021 to US$94.4 billion in 2025. The adjusted capital figures are higher than the reported total capital, suggesting adjustments that increase the capital value.
- Adjusted Debt to Capital
- The adjusted debt-to-capital ratio followed a similar pattern to the reported ratio, decreasing from 0.45 in 2021 to 0.39 in 2024, and then increasing to 0.43 in 2025. The adjusted ratio remained consistently close to the reported ratio throughout the period, indicating that the adjustments to debt and capital have a relatively balanced effect. The 2024 value represents the lowest ratio observed during the analyzed timeframe, while 2025 shows a return towards the levels seen in earlier years.
Overall, the company demonstrated increasing capital alongside fluctuating debt levels. The adjusted ratios provide a slightly modified view of the company’s leverage, but the core trends remain consistent with the reported figures. The increase in both debt and capital in 2025 warrants further investigation to understand the drivers behind these changes.
Adjusted Financial Leverage
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Adjusted total assets. See details »
3 Adjusted total equity. See details »
4 2025 Calculation
Adjusted financial leverage = Adjusted total assets ÷ Adjusted total equity
= ÷ =
An examination of the financial information reveals trends in adjusted financial leverage over a five-year period. Total assets exhibited a general upward trajectory, increasing from US$95,123 million in 2021 to US$110,343 million in 2025, with a slight decrease observed in 2024. Total shareholders’ equity also demonstrated consistent growth, rising from US$40,793 million in 2021 to US$53,407 million in 2025.
- Reported Financial Leverage
- Reported financial leverage decreased steadily from 2.33 in 2021 to a low of 1.96 in 2023, before increasing slightly to 2.07 in 2025. This suggests a decreasing reliance on debt financing relative to equity during the initial period, followed by a modest increase in leverage towards the end of the observed timeframe.
- Adjusted Total Assets & Equity
- Adjusted total assets mirrored the trend of reported total assets, increasing from US$94,265 million in 2021 to US$108,748 million in 2025, with a similar dip in 2024. Adjusted total equity also followed a consistent upward pattern, growing from US$43,973 million in 2021 to US$53,505 million in 2025.
- Adjusted Financial Leverage
- Adjusted financial leverage showed a consistent decline from 2.14 in 2021 to 1.92 in 2023. Similar to the reported leverage, it experienced a slight increase to 2.03 in 2025. The adjusted leverage ratio consistently remained below the reported leverage ratio throughout the period, indicating that adjustments to asset and equity values resulted in a more conservative leverage position. The convergence of the reported and adjusted leverage ratios in 2025 suggests a diminishing difference between the two calculations.
Overall, the company demonstrated a trend of decreasing financial leverage, as measured by both reported and adjusted ratios, for the majority of the period. The slight increase in leverage in 2025 warrants further investigation, but the general trend indicates improved financial stability and a reduced reliance on debt.
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Net profit margin = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Revenues
= 100 × ÷ =
2 Adjusted net income. See details »
3 2025 Calculation
Adjusted net profit margin = 100 × Adjusted net income ÷ Revenues
= 100 × ÷ =
The adjusted net profit margin exhibited a declining trend from 2021 to 2023, followed by a recovery through 2025. This analysis details the observed patterns and potential implications based on the presented financial figures.
- Adjusted Net Profit Margin Trend
- In 2021, the adjusted net profit margin stood at 19.31%. A significant decrease was observed in 2022, falling to 11.67%. This downward trend continued in 2023, with the margin reaching a low of 10.59%. However, a recovery began in 2024, increasing to 13.09%, and further improving to 14.20% in 2025. This indicates a stabilization and potential strengthening of profitability towards the end of the analyzed period.
- Relationship to Reported Net Profit Margin
- The adjusted net profit margin consistently tracked below the reported net profit margin across all years. The difference between the two margins suggests the presence of items impacting reported net income that are being excluded in the adjusted calculation. The gap between the reported and adjusted margins narrowed slightly from 2021 to 2023, then widened again in 2024 and 2025. This suggests changes in the nature or magnitude of these adjusting items.
- Revenue Correlation
- Revenues increased from 2021 to 2022, but then decreased in 2023. Revenues remained relatively stable between 2023 and 2024, before increasing again in 2025. The decline in adjusted net profit margin in 2022 and 2023 does not appear directly correlated to revenue fluctuations, suggesting that factors beyond sales volume, such as cost of goods sold or operating expenses, played a more significant role in the margin compression during those years. The subsequent margin improvement in 2024 and 2025 coincides with a slight revenue increase, indicating a potential positive relationship between revenue growth and profitability during the recovery period.
- Adjusted Net Income
- Adjusted net income mirrored the trend in the adjusted net profit margin, decreasing from US$7,571 million in 2021 to US$4,537 million in 2023, then increasing to US$6,325 million in 2025. This confirms that the margin fluctuations are directly driven by changes in adjusted net income.
Overall, the adjusted net profit margin demonstrates a period of decline followed by a recovery. Further investigation into the specific adjustments made to net income would be necessary to fully understand the drivers behind these fluctuations and assess the sustainability of the recent improvement.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROE = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ÷ =
2 Adjusted net income. See details »
3 Adjusted total equity. See details »
4 2025 Calculation
Adjusted ROE = 100 × Adjusted net income ÷ Adjusted total equity
= 100 × ÷ =
The adjusted return on equity (ROE) exhibited a declining trend from 2021 to 2023, followed by a period of recovery through 2025. This analysis details the observed patterns in adjusted ROE and its underlying components.
- Adjusted ROE Trend
- Adjusted ROE decreased from 17.22% in 2021 to a low of 9.42% in 2023. A subsequent increase was noted in 2024, reaching 11.17%, and continued into 2025, with adjusted ROE rising to 11.82%. The 2023 value represents the lowest point in the observed period.
- Adjusted Net Income
- Adjusted net income followed a similar pattern to adjusted ROE, declining from US$7,571 million in 2021 to US$4,537 million in 2023. It then increased to US$5,612 million in 2024 and further to US$6,325 million in 2025. The decrease in adjusted net income between 2021 and 2023 appears to be a primary driver of the initial decline in adjusted ROE.
- Adjusted Total Equity
- Adjusted total equity consistently increased throughout the period, moving from US$43,973 million in 2021 to US$53,505 million in 2025. This consistent growth in equity partially offset the impact of declining adjusted net income on adjusted ROE, particularly in the later years of the period. The increasing equity base would naturally exert downward pressure on ROE if net income remained constant.
- Comparison to Reported ROE
- Reported ROE also decreased from 2021 to 2023, but remained at a higher level than adjusted ROE in each year. The difference between reported and adjusted ROE suggests the presence of items impacting net income or equity that are being adjusted for in this analysis. Reported ROE showed a more moderate decline and stabilized between 12.55% and 12.83% from 2023 to 2025, while adjusted ROE demonstrated a more pronounced recovery during the same period.
The recovery in adjusted ROE from 2023 to 2025 is attributable to the combined effect of increasing adjusted net income and continued growth in adjusted total equity. While equity growth is consistent, the fluctuations in net income appear to have a more significant impact on the adjusted ROE calculation.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROA = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Total assets
= 100 × ÷ =
2 Adjusted net income. See details »
3 Adjusted total assets. See details »
4 2025 Calculation
Adjusted ROA = 100 × Adjusted net income ÷ Adjusted total assets
= 100 × ÷ =
The adjusted return on assets (ROA) exhibited fluctuations over the five-year period. Initial values were relatively high, followed by a significant decline, and then a partial recovery. A consistent trend is not readily apparent, suggesting the influence of specific operational or accounting adjustments in each period.
- Adjusted ROA Trend
- The adjusted ROA began at 8.03% in 2021, decreased substantially to 5.43% in 2022, and continued to fall to a low of 4.63% in 2023. A moderate increase was then observed in 2024, reaching 5.81%, and a further slight increase to 5.82% in 2025. This pattern indicates a period of diminishing profitability relative to adjusted assets, followed by a stabilization and modest improvement.
- Relationship to Adjusted Net Income
- The decline in adjusted ROA from 2021 to 2023 correlates with a decrease in adjusted net income. Adjusted net income fell from US$7,571 million in 2021 to US$4,537 million in 2023. The subsequent increases in both adjusted net income and adjusted ROA in 2024 and 2025 suggest a strengthening relationship between profitability and asset utilization.
- Relationship to Adjusted Total Assets
- Adjusted total assets generally increased throughout the period, rising from US$94,265 million in 2021 to US$108,748 million in 2025. The decrease in adjusted ROA between 2021 and 2023 occurred despite this asset growth, indicating that the increase in assets did not translate into a proportional increase in profitability. The stabilization of adjusted ROA in 2024 and 2025, alongside continued asset growth, suggests improved asset efficiency in those years.
The reported ROA generally tracked the adjusted ROA, though differences existed in each period. The gap between reported and adjusted ROA suggests the impact of specific adjustments made to net income and/or total assets. Further investigation into the nature of these adjustments would be necessary to fully understand their effect on the financial performance.